Theragen ETEX said Friday that it has
signed a memorandum of understanding with Bioneer to conduct research and
develop projects related to genome analysis jointly.
Under the accord, the two companies will
strategically cooperate on technology advancement research and services in the area
of next-generation sequencing, while planning to share research capabilities
and assets, support the mutual use of facilities and equipment, and exchange
information.
Theragen plans to utilize its
industry-leading research facilities, personnel, and technology in the field of
genome analysis, while Bioneer will use its key technologies in gene
technology, including the development of equipment and diagnostic kits.
“This agreement is
expected to result in not only R&D achievement but also business developments,”
Theragen ETEX CEO Hwang Tae-soon said. “We will do our best to make the most of
the advantages of both companies.”
Bioneer CEO Park Han-oh also said,
“Theragen ETEX's genomic analysis technology and Bioneer' s automation
equipment and related reagent will enable both companies to increase their
competitiveness in the domestic genomics analysis and diagnostic testing
market.”
